Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FOSTER CITY, Calif., October 21, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company’s upcoming contributions to the 18th European AIDS Conference (EACS 2021), taking place virtually and onsite in London from October 27-30. Forty-four studies from Gilead’s HIV research and development programs will be presented, including data from the global, observational, real-world BICSTaR study, which along with Gilead’s community-focused programs, reflect the company’s ongoing focus and
Dr. Elizabeth Clayborne, Adjunct Assistant Professor of Emergency Medicine at the University of Maryland School of Medicine and Emergency Physician at UM Capital Region Medical Center, joins Yahoo Finance to discuss the latest in the coronavirus pandemic.